Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest of Chemomab Therapeutics Ltd. from 31 Dec 2018 to 31 Dec 2024

Taxonomy & unit: us-gaap: USD
Description: Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.
Summary: Chemomab Therapeutics Ltd. annual and quarterly Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest in USD history and change rate from 31 Dec 2018 to 31 Dec 2024.
Chemomab Therapeutics Ltd. Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for the quarter ending 30 Jun 2024 was $3,631,000, a 54% increase year-over-year.
Chemomab Therapeutics Ltd. annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2024 was $13,945,000, a 42% increase from 2023.
Chemomab Therapeutics Ltd. annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2023 was $24,221,000, a 14% increase from 2022.
Chemomab Therapeutics Ltd. annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2022 was $28,180,000, a 126% decline from 2021.
Source SEC data: View on sec.gov

Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Annual (USD)

Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, YoY Annual Change (%)

Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Trailing 12 Months (USD)

Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Quarterly (USD)

Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, YoY Quarterly Change (%)

Chemomab Therapeutics Ltd. Annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest (USD)

Period	Value	YoY Chg	Change %	Start Date	End Date	Report	Filed	Fiscal Year	Fiscal Period
2024	$13,945,000	+$10,276,000	+42%	01 Jan 2024	31 Dec 2024	20-F	04 Apr 2025	2024	FY
2023	$24,221,000	+$3,959,000	+14%	01 Jan 2023	31 Dec 2023	20-F	04 Apr 2025	2024	FY
2022	$28,180,000	-$15,702,000	-126%	01 Jan 2022	31 Dec 2022	20-F	04 Apr 2025	2024	FY
2021	$12,478,000	-$18,429,000	-310%	01 Jan 2021	31 Dec 2021	20-F	28 Mar 2024	2023	FY
2020	$5,951,000	-$21,173,000	-78%	01 Jan 2020	31 Dec 2020	10-K	30 Mar 2022	2021	FY
2019	$27,124,000	+$13,632,000	+101%	01 Jan 2019	31 Dec 2019	10-K	09 Mar 2021	2020	FY
2018	$13,492,000			01 Jan 2018	31 Dec 2018	10-K	17 Mar 2020	2019	FY

Period	TTM Value	Value	YoY Chg	Change %	Start Date	End Date	Report	Filed	Fiscal Year	Fiscal Period
Q2 2024		$3,631,000	+$4,305,000	+54%	01 Apr 2024	30 Jun 2024	6-K	21 Aug 2024	2024	Q2
Q2 2023	$33,010,000	$7,936,000	-$1,202,000	-18%	01 Apr 2023	30 Jun 2023	6-K	21 Aug 2024	2024	Q2
Q1 2023	$31,808,000	$8,732,000	-$3,628,000	-71%	01 Jan 2023	31 Mar 2023	10-Q	11 May 2023	2023	Q1
Q4 2022	$28,180,000	$8,262,000			01 Oct 2022	31 Dec 2022	20-F	04 Apr 2025	2024	FY
Q3 2022		$8,080,000	-$5,112,000	-172%	01 Jul 2022	30 Sep 2022	10-Q	10 Nov 2022	2022	Q3
Q2 2022		$6,734,000	-$3,964,000	-143%	01 Apr 2022	30 Jun 2022	6-K	14 Aug 2023	2023	Q2
Q1 2022		$5,104,000			01 Jan 2022	31 Mar 2022	10-Q	11 May 2023	2023	Q1
Q3 2021		$2,968,000			01 Jul 2021	30 Sep 2021	10-Q	10 Nov 2022	2022	Q3
Q2 2021		$2,770,000			01 Apr 2021	30 Jun 2021	10-Q	12 Aug 2022	2022	Q2

* An asterisk sign (*) next to the value indicates that the value is likely invalid.